Focus on Anticoagulation Care

Back to articles

New data support apixaban over rivaroxaban for newly diagnosed VTE

February 11, 2019
  • Advising on this article:
  • Sarah Ray

KEY POINT

Use of apixaban (Eliquis—Bristol–Myers Squibb, Pfizer) appears to be more effective than rivaroxaban (Xarelto—Janssen) for prevention of recurrent venous thromboembolism (VTE) with a decreased risk of major bleeding events, according to results of a retrospective, observational study published in The Lancet Haematology.

SOURCES

Dawwas GK, et al. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol. 2019;6(1):e20–8.

Frere C, et al. The best direct-acting oral anticoagulant for treatment of venous thromboembolism. Lancet Haematol. 2019;6(1):e4–5.

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.